

S3 Table. Univariable and multivariable analyses for recurrence-free survival

	Univariable		Multivariable	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Non-interventional variables				
Age (yr)			Not included	
< 70	1			
≥ 70	1.4 (0.72-2.74)	0.321		
Sex			Not included	
Male	1			
Female	0.36 (0.11-1.19)	0.094		
cN				
Negative	1		1	
Positive	0.62 (0.28-1.36)	0.231	0.61 (0.28-1.36)	0.229
ypT				
ypT0-1	1		1	
ypT2+	3.33 (1.01-10.91)	0.048	2.64 (0.78-8.93)	0.117
ypN			Not included	
ypN1	1			
ypN2+	1.23 (0.61-2.47)	0.562		
No. of positive lymph nodes				
< 3	1		1	
≥ 3	1.8 (0.94-3.45)	0.078	2.29 (1.11-4.70)	0.024
Pathological stage			Not included	
ypT0/is/a and ypN+	1			
ypIIIA (T1-4a, N1)	3.20 (0.70-14.70)	0.135		
ypIIIB (T1-4a, N2-3)	3.55 (0.83-15.16)	0.088		
ypIVA (T4b or M1a)	11.94 (2.19-65.01)	0.004		
Interventional variables				
Adjuvant				
Not done	1		1	
Done	1.10 (0.57-2.15)	0.774	1.26 (0.63-2.50)	0.517
Adjuvant regimen			Not included	
MVAC	1			
Others	1.26 (0.34-4.74)	0.728		
Surgery			Not included	
Radical cystectomy	1			
Partial cystectomy	1.41 (0.43-4.61)	0.569		
LND			Not included	
Standard	1			
Extended	0.82 (0.43-1.59)	0.561		
Limited	1.89 (0.54-6.54)	0.317		
No. of LNs harvested				
< 20	1		1	
≥ 20	0.54 (0.27-1.09)	0.086	0.40 (0.18-0.88)	0.022
Surgical resection status			Not included	
R0	1			
R1	1.44 (0.63-3.27)	0.387		

CI, confidence interval; HR, hazard ratio; LN, lymph node; LND, lymph node dissection; MVAC, methotrexate, vinblastine, doxorubicin, and cisplatin.